Brief: Brii Biosciences Confirms Antibody Therapy Retains Neutralizing Activity Against Omicron Subvariants
27/07/2022 02:45
July 27 (Reuters) - Brii Biosciences Ltd 2137.HK :
* BRII BIOSCIENCES - CONFIRMS AMUBARVIMAB/ ROMLUSEVIMAB
COMBINATION RETAINS NEUTRALIZING ACTIVITY AGAINST OMICRON
SUBVARIANTS
Source text for Eikon: ID:
Further company coverage: 2137.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brii Biosciences
See all newsBrief: BRII Biosciences Discloses Launch Of BRISC, An SIRNA Therapeutics Discovery Platform
China's Brii Biosciences interim net loss narrows on lower R&D expenses
Brief: Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
Brief: Brii Biosciences Submits Demand For Arbitration Against VIR